The company reported a net loss of $9.1 million for FY2026 on minimal revenue, with ongoing liquidity challenges and a going concern warning. Key milestones included the commercial launch of MyoVista Insights™, the introduction of an AI-ECG marketplace, and a pending merger with Fortitude. Continue…
The company reported a net loss of $9.1 million for FY2026 on minimal revenue, with ongoing liquidity challenges and a going concern warning. Key milestones included the commercial launch of MyoVista Insights™, the introduction of an AI-ECG marketplace, and a pending merger with Fortitude. Continued operations depend on FDA clearance, additional funding, and successful merger completion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
